Salarius pharmaceuticals, inc. (FLKS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14
Grant revenue

3,942

3,465

1,858

1,452

1,533

1,056

1,175

1,120

1,210

1,274

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Net product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

989

698

112

0

-

0

0

-

-

-

-

Other revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

20

12

0

0

-

0

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

1,010

711

0

0

-

0

-

-

-

-

-

Operating expenses:
Cost of product revenue

-

-

-

250

-

430

-

545

511

506

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

662

529

307

197

0

0

0

0

-

-

-

Research and development

4,962

4,018

2,057

1,270

7,415

11,396

15,467

19,853

17,755

16,989

16,961

17,887

19,906

20,378

19,456

17,236

14,331

12,749

11,405

8,869

6,778

0

0

0

General and administrative

8,081

7,711

8,401

5,336

6,833

9,042

11,103

15,609

17,606

18,503

18,439

18,952

19,339

19,855

20,558

19,833

18,359

16,464

13,629

9,991

7,179

0

0

0

Total operating expenses

13,044

11,730

10,570

6,718

14,504

20,777

26,968

36,009

35,872

36,000

35,907

37,418

39,789

40,896

40,544

37,377

32,888

29,213

25,034

18,860

13,958

0

0

0

Loss before other income (expense)

-9,101

-8,265

-8,712

-5,265

-12,971

-19,721

-25,792

-34,888

-34,662

-34,725

-34,616

-35,942

-38,536

-39,886

-40,069

0

0

-

0

-

-

-

-

-

Change in fair value of warrant liability

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income net

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income from discontinued operations

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-18,860

-13,958

0

0

0

Interest income, net

-

-

-

67

-

152

-

253

273

291

311

332

367

393

346

263

171

72

43

36

22

0

0

0

Net loss

-7,498

-6,936

-7,543

-5,223

-12,890

-19,591

-25,611

-34,635

-34,388

-34,433

-34,305

-35,610

-38,169

-39,493

-39,485

-37,001

-32,716

-29,141

-24,990

-18,824

-13,935

0

0

0

Preferred dividends

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations attributable to common stockholders

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share — basic and diluted
Continuing operations (usd per share)

-

-

-0.73

-

-

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (usd per share)

-

-

0.00

-

-

-

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-8,262

-

-

-

0

0

-

-

-

-

-

-

-

-

-29,141

0

0

0

-

-

-

Net loss per share (usd per share)

-0.22

-0.67

-0.73

-0.08

-0.64

-0.11

-0.20

-0.50

-0.46

-0.46

-0.54

-0.51

-0.49

-0.48

-0.65

-0.71

-0.61

-0.51

-0.53

-0.47

-0.59

-1.82

-1.11

-1.42

Weighted-average number of common shares outstanding — basic and diluted

9,534

-10,972

3,605

18,068

2,372

18,067

1,653

18,037

17,893

17,642

17,386

17,130

16,873

16,619

16,361

16,105

15,843

15,551

15,290

15,034

10,179

2,061

1,797

1,539

Net product revenue
Total revenue

-

-

-

676

-

826

-

1,107

1,196

1,260

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Other revenue
Total revenue

-

-

-

7

-

11

-

12

13

13

0

0

0

-

-

-

-

-

-

-

-

-

-

-